8 results about "Carcinoembryonal antigen" patented technology

The invention provides an application of a carcino-embryonic antigen related cell adhesion molecule 5 (CEACAM5) in treatment of pancreatic cancer. Research finds that a novel stem cell-like cluster cell subtype (hereinafter referred to as' stem cell-like TCs') is found, and the subtype is significantly related to poor prognosis of pancreatic ductal adenocarcinoma patients. Therefore, the invention provides a novel pancreatic ductal adenocarcinoma treatment medicine, namely the carcino-embryonic antigen related cell adhesion molecule 5, which has very positive significance on the treatment of the pancreatic ductal adenocarcinoma.

The invention provides a papillary thyroid carcinoma neck lymph node metastasis risk prediction method and system based on blood indexes and TI-RADS grading, and relates to the technical field of medical data analysis. According to the method, an original data set is constructed by obtaining TI-RADS classification, the maximum diameter of nodules, the number of nodules, gender, age and conventional hematology indexes including apolipoprotein B and carcino-embryonic antigen of a patient, characteristic variables are screened by adopting LASSO regression, and an independent prediction risk factor model is established in combination with multi-factor Logistic regression. And further constructing a column graph model, carrying out performance verification through multiple statistical indexes, and deploying the model to a webpage calculator based on a shiyapp to realize convenient output of the individualized risk probability. According to the method, efficient and accurate prediction of the preoperative lymph node metastasis risk is realized, and reliable decision support can be provided for clinic.

The preparation method comprises the following steps: immobilizing a specific capture antibody Ab1 of a carcino-embryonic antigen on the surface of a gold electrode, closing a non-specific site by bovine serum albumin to obtain a BSA / Ab1 / GE working electrode, capturing the carcino-embryonic antigen, fusing the carcino-embryonic antigen with an enzyme-coated HHOF-Ab2 nano probe, and detecting the enzyme-coated HHOF-Ab2 nano probe to obtain the sandwich type electrochemical immunosensor based on the enzyme-coated hydrogen bond organic framework hybrid catalyst. The enzyme coated HOF-based sandwich type electrochemical immunosensor is obtained; the sensor specifically recognizes CEA through 'Ab1-CEA-Ab2' double antibody sandwich, the cyclic reaction of H2O2 and HQ is catalyzed by virtue of the enzyme-coated HOF nanoprobe to amplify a signal, and finally chemical change caused by oxidizing hydroquinone into benzoquinone is converted into quantifiable current by virtue of an electrochemical workstation, so that ultra-sensitive detection of CEA is realized, and the sensor has the advantages of high sensitivity, high response speed, strong specificity and the like.

The invention relates to a gastric cancer evaluation system based on a platelet subcellular structure, comprising: a data acquisition module for acquiring a carcino-embryonic antigen level in a blood sample of a detected subject and a platelet proportion in which alpha particles are regularly distributed; the data analysis and judgment module is used for jointly calculating the risk score of the subject suffering from the gastric cancer according to the platelet proportion of'regular distribution 'of alpha particles and the carcino-embryonic antigen level; and the result output module is used for outputting a corresponding gastric cancer assessment result according to the risk score. According to the platelet proportion of'regular distribution 'of alpha particles in a blood sample of a subject and the carcino-embryonic antigen level, the risk score of the subject suffering from the gastric cancer is jointly calculated, the risk of the subject suffering from the gastric cancer is judged, the specificity is 87.5%, and the sensitivity is 87.5%.

The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.

The invention relates to a nano composite material which is prepared by the following steps: mixing layered Ti3C2 and an aqueous dispersion of graphene oxide, and then adding a reducing agent and an intercalator for hydrothermal reaction to obtain a Ti3C2 / Gr material; and mixing and stirring the Ti3C2 / Gr material with a UIO-66-NH2 aqueous dispersion, carrying out centrifugal separation, adding a methylene blue aqueous solution, stirring, carrying out centrifugal separation, cleaning, and drying the precipitate to obtain the MB-coated UIO-66-NH2 / Ti3C2 / Gr nano composite material. According to the method, an MB-coated UIO-66-NH2 / Ti3C2 / Gr composite material is taken as a substrate, a carcino-embryonic antigen aptamer is fixed on the surface of a modified electrode through EDC and NHS, and non-specific adsorption sites on the modified electrode are sealed by bovine serum albumin, so that an electrochemical sensing interface for detecting carcino-embryonic antigens is constructed. The electrochemical adaptive sensor has the characteristics of strong specificity, high sensitivity, low detection limit and the like, and has important scientific significance and application value for detection of tumor markers.

The present invention relates to compositions for detecting a lung cancer disease, comprising peptide affinity ligands for detecting different combinations of proteins of different groups of biomarkers which include CYFRA 21-1, Prolactin, Squamous Cell Carcinoma Antigen (SCC), Her2 / Neu, Cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), C- reactive protein (CRP), Neuron Specific Enolase (NSE), C4 complement (C4), Interleukin 6 (IL-6), and Metallopeptidase Inhibitor 1 (TIMP-1). The invention further relates to methods of detecting or subtyping lung diseases, as well as to computer-implemented methods based on machine learning methods using expression data of the biomarkers.